150 related articles for article (PubMed ID: 16424642)
1. The role of protein kinase C-alpha in hematologic malignancies.
Lahn M; Sundell K; Köhler G
Acta Haematol; 2006; 115(1-2):1-8. PubMed ID: 16424642
[TBL] [Abstract][Full Text] [Related]
2. The role of protein kinase C-alpha in malignancies of the nervous system and implications for the clinical development of the specific PKC-alpha inhibitor aprinocarsen (Review).
Lahn MM; Sundell KL; Paterson BM
Oncol Rep; 2004 Feb; 11(2):515-22. PubMed ID: 14719093
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase C alpha expression in breast and ovarian cancer.
Lahn M; Köhler G; Sundell K; Su C; Li S; Paterson BM; Bumol TF
Oncology; 2004; 67(1):1-10. PubMed ID: 15459489
[TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
5. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of apoptosis proteins in hematological malignancies.
Fulda S
Leukemia; 2009 Mar; 23(3):467-76. PubMed ID: 19039324
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
Tolcher AW
Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides targeting protein kinase C-alpha, -beta I, or -delta but not -eta inhibit lipopolysaccharide-induced nitric oxide synthase expression in RAW 264.7 macrophages: involvement of a nuclear factor kappa B-dependent mechanism.
Chen CC; Wang JK; Lin SB
J Immunol; 1998 Dec; 161(11):6206-14. PubMed ID: 9834107
[TBL] [Abstract][Full Text] [Related]
10. The role of protein kinase C-alpha (PKC-alpha) in malignancies of the gastrointestinal tract.
Lahn M; Paterson BM; Sundell K; Ma D
Eur J Cancer; 2004 Jan; 40(1):10-20. PubMed ID: 14687784
[TBL] [Abstract][Full Text] [Related]
11. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma.
Wu TT; Hsieh YH; Hsieh YS; Liu JY
J Cell Biochem; 2008 Jan; 103(1):9-20. PubMed ID: 17486587
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
13. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
Roychowdhury D; Lahn M
Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
[TBL] [Abstract][Full Text] [Related]
14. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.
Lee YS; Dlugosz AA; McKay R; Dean NM; Yuspa SH
Mol Carcinog; 1997 Jan; 18(1):44-53. PubMed ID: 9022812
[TBL] [Abstract][Full Text] [Related]
15. Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications.
Zellner A; Fetell MR; Bruce JN; De Vivo DC; O'Driscoll KR
Clin Cancer Res; 1998 Jul; 4(7):1797-802. PubMed ID: 9676858
[TBL] [Abstract][Full Text] [Related]
16. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C as a target for cancer therapy.
Glazer RI
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):235-8. PubMed ID: 9212917
[No Abstract] [Full Text] [Related]
20. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
